Neurocrine Biosciences, Inc. (NBIX) Q1 2019 Earnings Results

Neurocrine Biosciences Misses on EPS — Stock Down 0.84%

Neurocrine Biosciences reported a larger-than-expected loss per share, which contributed to a slight decline in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's near-term performance. The defensive tone from management suggests they are aware of the challenges ahead but are focused on long-term strategies.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.12	N/A	-30.03%

Management

Management commentary

Tone: Defensive

Management expressed concern over the current financial performance, highlighting ongoing challenges. They remain committed to long-term strategies.

Management acknowledged the challenges faced this quarter.

They emphasized a focus on long-term growth despite current setbacks.

Neurocrine Biosciences Misses on EPS — Stock Down 0.84%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Misses on EPS — Stock Down 0.84%

Key numbers

Management commentary